Summary
Persistently elevated high‑sensitivity troponin T (hs‑TnT) in patients with single‑chamber leadless pacemakers is usually multifactorial. Beyond acute peri‑implant release, plausible contributors include: (1) chronic micro‑injury and fibrotic remodeling at the endomyocardial fixation site, (2) right‑ventricular pacing–related dyssynchrony with subclinical myocardial strain or pacing‑induced cardiomyopathy, (3) intermittent supply–demand mismatch during exertion or tachyarrhythmias, (4) device‑related complications such as microperforation/pericardial irritation (typically early), and (5) comorbid conditions—especially chronic kidney disease and chronic heart failure—that elevate baseline hs‑TnT. Careful trend analysis and correlation with pacing burden, renal function, and ventricular performance are essential for interpretation.
Pathophysiological Mechanisms
1) Implant‑site endomyocardial micro‑injury & remodeling
Fixation of an intracardiac device into the right‑ventricular (RV) endocardium can produce small, procedure‑related myocyte injury with measurable troponin release shortly after implantation. Although typically transient, ongoing micromotion at the anchoring interface and local fibrotic remodeling may sustain low‑grade troponin leakage in a subset of patients.
- Evidence: randomized/observational data show troponin rises after pacemaker lead fixation and after pacemaker implantation, consistent with minimal myocardial damage.
2) RV pacing burden → electrical & mechanical dyssynchrony
Chronic RV pacing produces non‑physiological activation, delayed LV free‑wall contraction, and interventricular/ intraventricular dyssynchrony. The resulting wall‑stress, adverse remodeling, and reduced pump efficiency (pacing‑induced cardiomyopathy in susceptible patients) can drive chronic low‑grade cardiomyocyte injury reflected in persistently elevated hs‑TnT, especially at higher pacing burdens.
3) Intermittent supply–demand mismatch & tachyarrhythmias
Periods of high heart rate, anemia, hypoxemia, or hypertensive surges during exertion can create type‑2 ischemia (supply–demand imbalance) without epicardial coronary occlusion. In paced ventricles with dyssynchrony, myocardial oxygen consumption may further increase, producing small hs‑TnT increments that accumulate on serial testing.
4) Device‑related complications (usually early)
Leadless systems avoid trans‑tricuspid leads but carry a recognized risk of RV perforation and pericardial effusion. These complications generally cause an acute troponin rise; low‑grade pericardial inflammation could, rarely, prolong hs‑TnT elevation. Late LPM infection is rare but can provoke inflammatory injury.
5) Comorbidity‑driven background elevation
hs‑TnT is chronically higher in chronic kidney disease (reduced clearance, uremic myocardial injury) and in structural heart disease/heart failure (ongoing myocyte turnover). In older adults with devices, these background factors frequently account for a substantial portion of the persistent elevation.
Clinical Reading of a Persistent hs‑TnT Elevation (Non‑ACS)
- Trend it: compare to each patient’s own baseline and look for dynamic change >
20%on serial tests. - Quantify pacing burden: high RV pacing percentage + LV dysfunction warrants evaluation for pacing‑induced cardiomyopathy and consideration of physiologic pacing strategies.
- Check the interface: echo for device position, pericardial effusion, and RV/LV function; correlate with thresholds and impedance trends.
- Adjust for kidney function: interpret hs‑TnT with eGFR in mind; elevations are common in CKD.
- Exclude triggers: fever/infection, uncontrolled hypertension, tachyarrhythmia, anemia, hypoxemia, or intense exertion.
This content is informational and not a substitute for clinical judgment.
Key Evidence (selected)
- Blažek P, et al. Pacemaker Implantation Associated Myocardial Micro‑injury. Sci Rep. 2018.
- Chen X, et al. Troponin T elevation after permanent pacemaker implantation. 2017.
- Mizner J, et al. Ventricular dyssynchrony and pacing‑induced cardiomyopathy. 2022.
- Naqvi TZ, et al. Adverse effects of RV pacing on cardiac function. 2023.
- Hauser RG, et al. Leadless pacemaker perforations & pericardial effusion. 2022.
- Aimo A, et al. Prognostic value of hs‑TnT in chronic heart failure. 2018.
- Geladari EV, et al. Cardiac troponin in chronic kidney disease. 2024.
- Whinnett Z, et al. Physiological pacing: mechanisms & indications. Eur Heart J. 2025.